TickerTalks
Browse all tickers →
TickerTalks›$AHR
AHAHR

American Healthcare REIT, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 2440× YoY at strong marginsStreet coverage with positive forward estimatesQuiet on X (23 mentions/wk)
$AHR·$12B·REIT - Healthcare Facilities·Real Estate
$54.31+1.3%1Y+31.9%
Mentions · last 7 days
2026-08-07: 5 posts2026-08-08: 2 posts2026-08-09: 0 posts2026-08-10: 6 posts2026-08-11: 7 posts2026-08-12: 0 posts2026-08-13: 3 posts230%
Price updated 8h ago·X counts updated 1d ago
AHAHR
$AHRAmerican Healthcare REIT, Inc.
$54.31+1.32%23 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AHR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-14

The move is getting stronger, with heavier trading behind it.

Healthcare REIT with SHOP-heavy portfolio delivering FFO growth — consensus walks EPS $0.57 → $1.04 across FY26-28, freshly priced equity offering is the funding lever.

American Healthcare REIT's quarterly revenue history is noisy (Q2 shows a data-artifact spike to $1.32T that clearly reflects a units/reporting-format issue, with realistic prints of $573M–$650M in the surrounding quarters) — the underlying REIT is running with healthcare-facility rents at 98%+ gross margin as recorded.

  • Consensus FY26 revenue $2.65B / EPS $0.57 walking to $2.91B / $0.81 FY27 and $3.02B / $1.04 FY28 (3–4 analysts) — a ~40% EPS step-up in each of the next two years, consistent with a SHOP-portfolio net-operating-income recovery.
  • Company priced a public offering of common stock this window — dilutive but the standard REIT funding lever for portfolio additions; the estimate walk already reflects post-offering share count.
  • +32% over 12 months, position 73% of 52-week range, +2% above 50-day and +7% above 200-day MA, beta 0.77 — the tape has re-rated on the SHOP-recovery narrative without becoming stretched.

Next print 2026-11-05 is where SHOP occupancy trajectory, updated 2026 AFFO guide, and any acquisition-pipeline commentary either extend the acceleration or expose that the recovery is fully priced.

What to watch: November 5 Q3 print — SHOP portfolio occupancy trajectory, AFFO/share vs consensus, acquisition-pipeline dollar value, dividend commentary, and use-of-proceeds for the equity offering.

On the calendar: 2026-11-05 — Q3 2026 earnings

Read the AI verdict + X sentiment for $AHR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Healthcare REIT owning senior housing, medical office, and skilled nursing facilities across the US after merging two Griffin-American trusts.

Industry overviewAI analysisGenerated by AI from underlying data

Where REIT - Healthcare Facilities sits in its cycle right now — and what that implies for $AHR.

REIT - Healthcare Facilities · Real Estate

No material change from last week — the Silver Tsunami accelerating in 2026 as the oldest boomers reach 80 creates a durable multi-year demand runway for senior housing and memory care capacity.

Industry benchmark

4-name peer basket
+20.3%YTD
+17.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
80.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
25.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
5.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
98.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$0.16$0.14+16.6%
Q1 2026May 7, 2026$0.13$0.16-19.2%
Q4 2025Feb 26, 2026$0.06$0.15-61.3%
Q3 2025Nov 6, 2025$0.33$0.42-21.4%
Next earningsThu, Nov 5·consensus EPS $0.15

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$1.32T+244022.7%98.1%21.7%$0.16—
Q1 FY26$650.8M+20.4%-1.3%6.5%$0.13$49.7M
Q4 FY25$604.1M+11.3%0.1%6.6%$0.06$-14.1M
Q3 FY25$572.9M+9.4%20.7%7.4%$0.33$155.3M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.6B$2.6B – $2.8B$0.57$0.56 – $0.584
FY27$2.9B$2.8B – $3.1B$0.81$0.78 – $0.834
FY28$3.0B$2.9B – $3.2B$1.04$1.01 – $1.071
FY29$3.5B$3.4B – $3.7B$1.52$1.46 – $1.641
FY30$4.0B$3.9B – $4.3B$0.00$0.00 – $0.001

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.77%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+3.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 191.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.775-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 26Brian PeayCFO25.0K sh$1.3MSellJun 24Mark E. FosterEVP, GC & Secretary2.5K sh$121KSellMar 25Mark E. FosterEVP, GC & Secretary2.0K sh$97K
+ 30 other (14 awards · 8 inkinds · 8 exempts) in window

See when $AHR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 11424B5
AI summary

American Healthcare REIT (AHR) is conducting a forward equity offering of 13,250,000 shares of common stock (or up to 15,237,500 shares if the underwriters' overallotment option is exercised in full), with shares borrowed from third parties and sold to underwriters by forward purchasers rather than directly by the REIT. AHR does not receive proceeds at closing; instead, it expects to physically settle the forward sale agreements within approximately 24 months and receive the proceeds at settlement. The NYSE closing price on August 10, 2026 was $55.47 per share. The REIT structure means shares are subject to ownership limitations, and cash or net-share settlement alternatives could reduce or eliminate proceeds to the company depending on circumstances.

424B5Prospectus supplement (offering)Aug 10424B5
AI summary

AHR (AHR) filed a prospectus supplement (Form 424B5) on 2026-08-10 for an immediate offering of 13,250,000 Shares $56.74 per share, raising approximately $0.01 . Use of proceeds: general corporate purposes. This is dilutive capital activity happening now, distinct from a shelf registration — new shares will be issued. Investors should assess pricing relative to market and stated use of proceeds to evaluate dilution impact.

8-KMaterial agreementAug 108-K — Item 1.01: Material agreement
AI summary

American Healthcare REIT, Inc. (AHR) entered into partnership, American Healthcare REIT Holdings, LP, a Delaware limited partnership, or Buye with a counterparty on 2026-08-10, involving $873,000,000, . Effective Date, we, through our operating partnership, American Healthcare REIT. This is a material definitive agreement (Item 1.01) requiring immediate disclosure under SEC rules. Investors should review the agreement terms for financial obligations, dilution, or strategic implications.

8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

AHR filed an 8-K (Item 2.02) reporting its financial results, filed 2026-08-06. The actual financial figures are in the attached press release (Exhibit 99.1), not reproduced in the body excerpt. This is a material disclosure; investors should review the press release for beat/miss details and guidance.

8-KOfficer or director changeJul 228-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

AHR filed an 8-K (Item 5.02) reporting a director or officer change. not to u is involved in the change. The role noted: Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory A. This is primarily an administrative disclosure; materiality depends on the seniority of the role and whether it reflects a strategic shift.

8-KShareholder voteJun 258-K — Item 5.07: Shareholder vote
AI summary

AHR filed an 8-K (Item 5.07) disclosing the results of stockholder voting at its annual or special meeting. Vote disclosures are routine governance filings; contested results (e.g., failed say-on-pay) would be the indicator of significance.

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

AHR filed an 8-K (Item 7.01) for a Regulation FD disclosure. A presentation or investor communication is being furnished as an exhibit. Reg FD disclosures are furnished rather than filed and are not typically market-moving on their own, but may contain forward-looking statements or strategy updates.

424B5Prospectus supplement (offering)May 21424B5
+ 22 other (7 13Gs · 6 8-Ks · 3 routine 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Is American Healthcare REIT, Inc. (AHR) Outperforming Other Finance Stocks This Year?zacks.com·18h agoE. Ohman J or Asset Management AB Invests $2.91 Million in American Healthcare REIT, Inc. $AHRdefenseworld.net·3d agoAmerican Healthcare REIT Announces Pricing of Public Offering of Common Stockbusinesswire.com·4d agoAmerican Healthcare REIT Announces Public Offering of Common Stockbusinesswire.com·5d agoAmerican Healthcare REIT, Inc. (AHR) Q2 2026 Earnings Call Transcriptseekingalpha.com·7d ago

More in REIT - Healthcare Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LTC$WELL$DOC$NHI$SBRA
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport